Navigation Links
TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
Date:7/6/2012

SUNNYVALE, Calif., July 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson's disease and Traumatic Brain Injuries (TBI) centered on its proprietary anti-apoptotic therapeutic protein known as MANF, today announced that its President & CEO Gerald E. Commissiong was interviewed by TheStockRadio.com following Amarantus' recent presentation at the National Investment Banking Association conference. To listen to the full in-depth interview, please visit http://thestockradio.com/gerald-e-commissiong-ceo-of-amarantus-biosciences-inc-otcambs/1081.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and TBI. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS: Amarantus BioSciences, Inc. Gerald E. Commissiong 408.737.2734 x 102 pr@amarantus.com

 

 


'/>"/>
SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ion Proton™ Sequencer - Inventor, Dr. M. Jonathan Rothberg and Life Technologies CEO, Greg Lucier, Available for Interviews at CES Today
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
4. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
5. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
6. Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan
7. Tanke BioSciences To Host Leading Symposium On Food Safety, June 24-25
8. Entia Biosciences Receives Patent for Use of Ergothioneine in Foods and Beverages
9. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
10. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
11. Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 21, 2017 , ... Building on the success of the inaugural ... on the very latest developments in radical life extension. RAADfest combines cutting edge science ... the empowerment of personal development, making it the largest most comprehensive and inclusive super ...
(Date:6/22/2017)... CA (PRWEB) , ... June 22, 2017 , ... ... global health leaders in designating infertility as a disease, bringing new hope for ... week at their 2017 annual meeting to back the World Health Organization’s designation ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell Consulting’s ... and life sciences industries, continue to be in demand for their insights and ... be speaking on “The State of Information Governance in the Biopharmaceutical Industry” at ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... the release of Limfinity® version 6.5, a content-packed update to the Limfinity® framework. ... gain a larger and more diverse base of customers among labs and other ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):